Key data catalysts for the industry’s small players
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Significant readouts for small players
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
